title: Effect of monthly administration of GHRH (fragment 1-29) with osmotic pump on the rat anterior pituitary.
abstract: Growth Hormone-Releasing Hormone (GHRH) is the main factor, which regulates GH secretion and somatotrope proliferation. However, its chronic effect on anterior pituitary gland is still unknown. It is known that excessive GHRH secretion in patients with gastroenteropancreatic tumors secreting GHRH results in acromegaly and somatotrope hyperplasia. In mice transgenic for GHRH somatotrope tumors develop. Thus, the aim of this paper was to examine the effect of GHRH chronic administration on somatotrope secretion, their percentage and cell proliferation in anterior pituitary gland in rats. The experiment was performed on male Fischer 344 rats weighing 200+/-20 g. The animals were divided into two groups: group I-controls (13 rats) received solvent for GHRH (5% ethanol in demineralized water); group II (10 rats) received GHRH (Growth Hormone Releasing Factor, fragment 1-29 amide) at a dose of 5 microg/day. The substances were given for 1 month via osmotic pump (ALZET), which were implanted subcutaneously in the dorsal region under ketamin anesthesia. After 4 weeks all rats were decapitated and the blood was collected. In the microscopic preparations of anterior pituitary gland the morphology of pituitary (Herlant staining) and the percentage of somatotrope cells and proliferation index based on PCNA staining were assessed. It was found that the chronic treatment with GHRH caused a statistically significant increase in serum rGH concentration and in percentage of somatotropes, but did not change proliferation index and did not induce pathological changes in the morphology of the anterior pituitary gland when compared to the control group. Summing up, monthly GHRH administration did not induce somatotrope adenomas but it caused serum GH level elevation, what seems to depend partially on the increase of somatotrope number.
authors.affiliation: Department of Immunoendocrinology, Medical University of Łodź, Poland. emotylek@poczta.onet.pl
authors.forename: Ewelina
authors.initials: E
authors.lastname: Motylewska
authors.forename: Gabriela
authors.initials: G
authors.lastname: Mełeń-Mucha
authors.forename: Sławomir
authors.initials: S
authors.lastname: Mucha
authors.forename: Marek
authors.initials: M
authors.lastname: Pawlikowski
mesh_terms: D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects*; D003692:Delayed-Action Preparations; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D013006:Growth Hormone / Q000187:drug effects* / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage*; D007260:Infusion Pumps; D007262:Infusions, Intravenous; D008297:Male; D010903:Pituitary Gland, Anterior / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344
chemical_list: D003692:Delayed-Action Preparations; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone